Skye Bioscience, Inc. Enters into Collaboration and License Agreement with Halozyme, Inc.

Skye Bioscience, Inc. has entered into a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. effective December 18, 2025. Under this agreement, Halozyme grants Skye Bioscience a non-exclusive license to utilize its ENHANZE® drug delivery technology for the development of a subcutaneous formulation of nimacimab. Halozyme will also serve as the exclusive supplier for clinical and commercial quantities of the API for Halozyme’s rHuPH20 bulk drug product. Skye Bioscience is obligated to make milestone payments contingent upon specific development, commercialization, and net sales achievements for the nimacimab product. Additionally, the company will pay mid-single digit royalties based on worldwide net sales. The agreement incorporates standard provisions for termination, representations, warranties, covenants, and indemnification.